Ashland Reveals New Corporate Identity
The company revealed its new Always Solving corporate identity following its eventual separation from Valvoline.
On Oct. 3, 2016, Ashland revealed a new corporate identity, Always Solving, furthering its competitive strategy following its eventual separation from Valvoline. In a press announcement, the company said Always Solving reflects the company’s positioning and people across diverse industries as broad as pharmaceuticals, automotive, personal care, paints, adhesives, biofunctionals, and more.
Bill Wulfsohn, Ashland CEO and chairmen, developed a competitive strategy that empowers each of Ashland’s chemical businesses to develop its own comprehensive strategic approach as to where to compete and how to win in their marketplace. Ashland will continue fostering growth through a pipeline of innovations and sales opportunities and continue capturing value delivered to customers while driving its cost competitiveness.
In a press announcement, the company reiterated its corporate focus on safe, compliant, and responsible operations and commitment to doing business with integrity and respect for all people and the world. The company has made formal commitments to improve the environmental, health, safety, and security performance for facilities, processes, and products throughout the entire operating system. Forty-six Ashland sites have received Responsible Care certification, including three facilities earlier this year.
Source: Ashland
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
